Commentary

Long COVID risk - a signal to address sex hormones and women's health

Stuart Stewart\textsuperscript{a,b,*}, Louise Newson\textsuperscript{c}, Tracy A Briggs\textsuperscript{d,e}, Dimitris Grammatopoulos\textsuperscript{f,g}, Lawrence Young\textsuperscript{d}, Paramjit Gill\textsuperscript{f}

\textsuperscript{a} Centre for Primary Care and Health Services Research, Division of Population Health, Health Services Research & Primary Care, The University of Manchester, Manchester, UK
\textsuperscript{b} National Institute for Health Research – Academic Clinical Fellow in General Practice (award ref: ACF-2016-06-013)
\textsuperscript{c} Newson Health Menopause and Wellbeing Centre, Church Street, Stratford-upon-Avon, UK
\textsuperscript{d} NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK
\textsuperscript{e} Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK
\textsuperscript{f} Warwick Medical School, University of Warwick, Coventry, UK
\textsuperscript{g} Institute of Precision Diagnostics and Translational Medicine, University Hospital Coventry and Warwickshire (UHCW), NHS Trust, Coventry, UK

The COVID-19 pandemic has brought health inequalities into sharp focus on an international scale. Vulnerability to and mortality from acute COVID-19 infection is higher in men [1], whereas, Long COVID disproportionately affects women [2]. Why?

A recent review [3] on Long COVID highlights the multi-organ sequelae following infection, articulating a pressing need for greater understanding of the mechanisms in the post-acute phase, to guide research for effective management. Underlying mechanisms include virus-associated pathologies, immunological dysfunction and inflammatory-mediated damage [3]. However, despite the stark asymmetry in risk and outcomes between sexes, sex-specific pathophysiology receives little attention in this review [3].

Sex-specific risk and ultimately outcomes are multifactorial - a function of the complex interplay between biology, behaviour, and the wider determinants of health. Wenham et al. [4] describe important factors which result in disproportionate risk to women's socio-economic positions and health during the COVID-19 pandemic. These factors set the stage for the disproportionate impact that Long COVID has on women. Female sex and age under 50 years are now acknowledged as risk factors for Long COVID [2]. However, recognised predictors of acute COVID mortality risk [1] (increasing age, chronic comorbidity, male sex) fail to predict poor outcomes in Long COVID.\textsuperscript{2}

In fact, Long COVID risk appears to be largely unaffected by pre-existing comorbidities or disability [2], making identification of at-risk women more difficult – a problem for both women and clinicians. Despite the already vulnerable socioeconomic positions of women during the pandemic, their ability to return to work is further impeded by the chronicity of symptoms of Long COVID. This situation is likely far more challenging for perimenopausal and menopausal women who already experience significant and additional inequality in the workplace [5].

From a biological perspective, we propose the asymmetry in risk and outcomes between sexes, and an overlap of symptoms of Long COVID [3] with those of perimenopause and menopause [6] point towards sex hormone differences as targets for further investigation. Furthermore, the higher prevalence of Long COVID in women under the age of 50 years [2] is an important and supporting clue as the mean age of natural menopause (in the UK) is 51 years [6].

Oestrogen and androgen receptors are ubiquitous, present in almost all tissues in the body, evidencing the widespread and important roles of sex hormones [7], well beyond their obvious roles in the reproductive system. Viral-induced sex hormone dysfunction resulting in early menopause, menstruation abnormalities and miscarriage are documented in HIV and Hepatitis B and C infections [8]. In the context of viral infections, sex hormone dysfunction may be related to multisystem disruption or due to organ-specific effects [8]. The role of sex hormones in COVID-19 infection are now beginning to emerge. A recent study [9] highlights important clinical and immunological differences between sexes in acute COVID-19 infection; women had lower mortality, lower levels of inflammation, higher lymphocyte counts, and faster antibody responses than men. Specifically, oestriadiol may be implicated here [7] owing to its immunomodulatory effects [7] as well as antiplatelet and vasodilatory activity [7]. Observational research [8] highlights transient menstruation abnormalities during acute COVID-19 possibly owing to the expression of the ACE2 receptor proteins in the ovaries [8]. Such findings support a hypothesis of temporary disruption to physiological ovarian steroid hormone production, which could acutely exacerbate symptoms of perimenopause and menopause.

Many symptoms of Long COVID [3] (fatigue, muscle aches, palpitations, cognitive impairment, sleep disturbance) have a significant overlap with the perimenopause and menopause [6], both which can affect women of all ages. Such overlap may create diagnostic uncertainty and requires clinicians to assess for this additional diagnosis as...
it offers an opportunity to treat perimenopausal and menopausal symptoms with safe and effective hormone replacement therapy (HRT) [6]. Failure to recognise this overlap misses an opportunity to treat many debilitating symptoms affecting both physical and mental health, but also to reduce some women’s risk of cardiovascular disease, type 2 diabetes, osteoporosis, obesity and possibly dementia [6]—all of which increase after the menopause. Furthermore, it could lead to women with symptoms of the perimenopause and menopause being misdiagnosed with Long COVID.

Identification of patients at highest risk of Long COVID is now of great importance [23]. This allows prioritisation of resources for those in greatest clinical need, along with identifying multi-speciality teams [2]. Clinicians working in Long COVID clinics should receive training in menopause care so perimenopausal and menopausal women can be promptly diagnosed and offered appropriate management. Screening for and diagnosis of perimenopause and menopause is simple and quick, does not usually involve serum sex hormone analysis [6], and should be routinely performed in all women in Long COVID clinics. Changes in menstruation are often early signs of perimenopause [6]; other common symptoms of perimenopause and menopause include hot flushes, memory problems, brain fog, reduced stamina, fatigue, anxiety, low mood, joint pains and headaches [6]. Clinicians should actively enquire about all of these symptoms. Where appropriate, a trial of HRT is a safe and useful treatment option [6] for women and clinicians to consider, as an improvement in symptoms supports a diagnosis of hormone deficiency.

Failure to explore sex-specific risk and outcomes in COVID-19 is unethical [10] and associated with several risks. Firstly, it threatens opportunities for identifying mechanisms and treatment targets, where at present, no treatments exist. Secondly, it threatens global women’s health at present and in the future, owing to the risk of misdiagnosing Long Covid instead of the perimenopause and menopause, and failing to implement appropriate treatment strategies. Thirdly, it threatens global economic recovery and future preparedness due to the highly gendered nature of work and female dominated sectors such as health and social care [4].

Looking ahead, there is urgent need for robust research to help understand the epidemiological basis, as well as the underlying biological mechanisms for sex-differences in Long COVID. The deficit in sex and gender-specific outcomes within clinical trials is recognised, with calls for the systematic application of sex-specific methodologies [10]. Sex-disaggregated data underpins this vital research, along with power calculations which consider sex as an analytical variable a priori [10].

Contributors

Dr. Stuart Stewart: writing - original draft preparation (lead); writing – review & editing of revision (lead)
Dr. Louise Newson: writing – original draft preparation (supporting); writing – review & editing of revision (supporting)
Dr. Tracy A Briggs: writing – original draft preparation (supporting); Professor Dimitris Grammatopoulos: writing - original draft preparation (supporting); writing – review & editing of revision (supporting)
Professor Lawrence Young: writing - original draft preparation (supporting); writing – review & editing of revision (supporting)
Professor Paramjot Gill: writing - original draft preparation (supporting); writing - review & editing of revision (supporting)

Declaration of interests

SS: Dr. Stewart reports - SS is an Institute of Health Research (NIHR) academic clinical fellow (ACF). All views are those of SS and co-authors and do not necessarily represent those of the NIHR. Award ref: ACF-2016-06-013

LN: Dr. Newson reports - LN is an advisor to the National Health Service (NHS) national menopause programme. The views expressed in this publication are those of LN and do not necessarily represent those of NHS national menopause programme. LN is a director of Newson Health which provides private holistic clinical menopause and wellbeing care.

TB: None declared
DG: None declared

LY: LY is a member of Abingdon Health Medical and Scientific Advisory Board. The views expressed are those of my LY and my co-authors and do not necessarily represent the views of Abingdon Health Medical and Scientific Advisory Board.

PG: Professor Gill reports - PG is a trustee of the South Asian Health Foundation and receive support from the National Institute for Health Research (NIHR) Applied Research Collaborations West Midlands, and an NIHR Senior Investigator. The views expressed in this publication are those of the authors and not necessarily represent those of the NIHR or the UK Department of Health and Social Care.

Acknowledgements

All: No authors received any financial payment in exchange for writing this commentary.

SS: SS is funded by the National Institute for Health Research (NIHR) as an academic clinical fellow (ACF) in General Practice - (award ref: ACF-2016-06-013). The views expressed in this publication are those of the authors and do not necessarily represent those of the NIHR.

LN: LN is an advisor to the National Health Service (NHS) national menopause programme. The views expressed in this publication are those of LN and do not necessarily represent those of NHS national menopause programme. LN is a director of Newson Health which provides private holistic clinical menopause and wellbeing care. Neither the NHS national menopause programme nor Newson Health had any involvement in funding the creation of this commentary.

TB: None declared
DG: None declared
LY: None declared
PG: Professor Gill reports - PG is a trustee of the South Asian Health Foundation and receives support from the National Institute for Health Research (NIHR) Applied Research Collaborations West Midlands, and a NIHR Senior Investigator. The views expressed in this publication are those of the authors and not necessarily represent those of the NIHR or the UK Department of Health and Social Care.

References

[1] Docherty AR, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; May 22;369:m1985.
[2] Sigfusdottir I, Drake TM, Pauley E, Jusdason EC, Ollaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Respir Med 2021 May;395(10227):846–8.
[3] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021 Apr;27(4):601–15.
[4] Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. The Lancet 2020 Mar;395(10227):8–15.
[5] UK Parliament, Committees, Women and Equalities Committee. An invisible cohort: Why are workplaces failing women going through menopause? [Internet]. UK Parliament | Committees; 2021. [cited 2021 Sep 1]. Available from: https://committees.parliament.uk/committee/328/women-and-equalities-committee/news/156760/an-invisible-cohort-why-are-workplaces-failing-women-going-through-menopause/
[6] National Institute for Health and Care Excellence. NICE [UK] | Menopause [Internet]. Clinical Knowledge Summaries. [cited 2021 Aug 28] Available from: https://cks.nice.org.uk/topics/menopause/.
[7] Straub RH. The Complex Role of Estrogens in Inflammation. Endocr Rev 2007 Aug 1;28(5):521–74.

[8] Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online 2021 Jan;42(1):260–7.

[9] Huang B, Gai Y, Li N, Li K, Wang Z, Li L, et al. Sex-based clinical and immunological differences in COVID-19. BMC Infect Dis 2021 Dec;21(1):647.

[10] Brady E, Nielsen MW, Andersen JP, Oertelt-Prigione S. Lack of consideration of sex and gender in COVID-19 clinical studies. Nat Commun 2021 Dec;12 (1):4015.